SCHEMBL6582500

SCHEMBL6582500

Cc1ccccc1S(=O)(=O)n1cccn1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.54
POLB P06746 1/20 0.49
PKM P14618 1/20 0.49
RAPGEF4 Q8WZA2 1/20 0.46
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
ELANE P08246 1/20 0.41
CTSG P08311 1/20 0.40
CMA1 P23946 1/20 0.40
ALDH1A1 P00352 3/20 0.39
TP53 P04637 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
HTR2A P28223 1/20 0.37
HTR2C P28335 1/20 0.37
EPHX2 P34913 1/20 0.36
GRM4 Q14833 1/20 0.36
KDM4E B2RXH2 2/20 0.36
L3MBTL1 Q9Y468 2/20 0.36
SLC40A1 Q9NP59 1/20 0.35
MAPT P10636 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4969961 0.81 GAA (0.46) GAAPOLBPKMRAPGEF4MEN1
SCHEMBL24254286 0.79 GAA (0.54) GAAPOLBPKMELANEEPHX2
SCHEMBL29391601 0.79 GAA (0.54) GAAPOLBPKMELANEEPHX2
SCHEMBL4254051 0.74 POLB (0.54) GAAPOLBPKMMEN1KMT2A
SCHEMBL3316587 0.74 CA1 (0.55) GAAPOLBPKMRAPGEF4MEN1
SCHEMBL27461811 0.73 ELANE (0.47) GAARAPGEF4ELANECTSGCMA1
SCHEMBL19204884 0.73 GAA (0.62) GAAPOLBPKMRAPGEF4ALDH1A1
SCHEMBL6024620 0.72 RAPGEF4 (0.53) RAPGEF4CTSGCMA1ALDH1A1TP53
SCHEMBL5694032 0.71 GAA (0.42) GAAPKMRAPGEF4CTSGCMA1
SCHEMBL4727160 0.71 HTT (0.57) RAPGEF4MEN1KMT2ACTSGCMA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1257539-B1 AMINO PYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF OBESITY AND OTHER DISORDERS ORTHO MCNEIL PHARM INC (US) 2004-12-29 EP disclosed
US-6531478-B2 For therapy of eating disorder, obesity, bulimia nervosa, diabetes, binge eating, anorexia nervosa, dyslipidimia, hypertension, memory loss, epileptic seizures, migraine, sleep disturbances, pain, sexual/reproductive disorders KORDIK CHERYL P (US) 2003-03-11 US disclosed
EP-1257539-A2 AMINO PYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF OBESITY AND OTHER DISORDERS Ortho-Mcneil Pharmaceutical, Inc. (US) 2002-11-20 EP disclosed
US-20020065289-A1 Amino pyrazole derivatives useful for the treatment of obesity and other disorders KORDIK CHERYL P (US) 2002-05-30 US disclosed
WO-2001062737-A2 AMINO PYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF OBESITY AND OTHER DISORDERS ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2001-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020065289-A1 Amino pyrazole derivatives useful for the treatment of obesity and other disorders NPY5R, NPY1R, NPY4R GAA 2262/4885POLB 4444/4885PKM 965/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.